It is highly likely that it does work, but opening it up to Australians is not demonstrative of that. I think the company have done this so that if and when it is announced to be successful, Australia will have some skin in the game. And from a PR point of view it looks better if Australians were accessing life saving product during the trial. It gives the company a national stamp right before the lid blows off.
That said, if the trial is stopped early imminently, as many are hoping and predicting, then chances are there'll be no Australians in the trial. Or am I missing something?
Ann: Ethics Approval to Treat COVID-19 Patients in Australia, page-207
-
- There are more pages in this discussion • 114 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |